STUDY OBJECTIVE: This burden-of-illness study on osteoporosis was performed with the main goal to estimate the economic implications of osteoporosis for the Slovenian healthcare system. METHODS: A variety of sources was used to quantify the utilization of resources in 2003, and the appropriate unit costs were assigned to the identified resources. MAIN OUTCOME MEASURES: The study included all direct and indirect costs that arise from treatment of osteoporosis and consequent hip, spine and wrist fractures in total Slovene postmenopausal population in 2003. RESULTS: We estimated the total burden of postmenopausal osteoporosis in Slovenia for 2003 to be over SIT 7.55 billion (approximately 31.5 million euros); among that, 45% or SIT 3.39 billion (14.2 million euros) belong to drug expenditures for osteoporosis treatment and prevention; 29% or SIT 2.2 billion (9.2 million euros) include indirect costs for osteoporosis morbidity and mortality, and 26% or SIT 1.95 billion (8.1 million euros) belong to direct costs for treatment, hospitalization, and rehabilitation of osteoporotic fractures. Total costs on osteoporotic fractures were however subject to an approximation due to the expert panel-based estimate of proportion of osteoporosis-caused fractures and the limited data on resource utilization for fracture treatment. CONCLUSION: Osteoporosis is a costly disease with a significant burden to society and needs to be viewed as an important problem with a complex long-term impact.
STUDY OBJECTIVE: This burden-of-illness study on osteoporosis was performed with the main goal to estimate the economic implications of osteoporosis for the Slovenian healthcare system. METHODS: A variety of sources was used to quantify the utilization of resources in 2003, and the appropriate unit costs were assigned to the identified resources. MAIN OUTCOME MEASURES: The study included all direct and indirect costs that arise from treatment of osteoporosis and consequent hip, spine and wrist fractures in total Slovene postmenopausal population in 2003. RESULTS: We estimated the total burden of postmenopausal osteoporosis in Slovenia for 2003 to be over SIT 7.55 billion (approximately 31.5 million euros); among that, 45% or SIT 3.39 billion (14.2 million euros) belong to drug expenditures for osteoporosis treatment and prevention; 29% or SIT 2.2 billion (9.2 million euros) include indirect costs for osteoporosis morbidity and mortality, and 26% or SIT 1.95 billion (8.1 million euros) belong to direct costs for treatment, hospitalization, and rehabilitation of osteoporotic fractures. Total costs on osteoporotic fractures were however subject to an approximation due to the expert panel-based estimate of proportion of osteoporosis-caused fractures and the limited data on resource utilization for fracture treatment. CONCLUSION:Osteoporosis is a costly disease with a significant burden to society and needs to be viewed as an important problem with a complex long-term impact.
Authors: A J Rosner; D T Grima; G W Torrance; C Bradley; J D Adachi; R J Sebaldt; D J Willison Journal: Pharmacoeconomics Date: 1998-11 Impact factor: 4.981
Authors: M Jürisson; H Pisarev; J Kanis; F Borgström; A Svedbom; R Kallikorm; M Lember; A Uusküla Journal: Osteoporos Int Date: 2016-02-23 Impact factor: 4.507